血清miRNA-24和miRNA-509在肝细胞癌患者血清中的表达及与预后的关系

doi:10.11904/j.issn.1002-3070.2023.05.004

实用肿瘤学杂志 ›› 2023, Vol. 37 ›› Issue (5): 411-415.doi: 10.11904/j.issn.1002-3070.2023.05.004

血清miRNA-24和miRNA-509在肝细胞癌患者血清中的表达及与预后的关系

庞武¹, 陈莉江¹, 朱宇¹, 吴涯昆¹, 张伟²

1.四川省遂宁市中心医院肝胆外科(遂宁 621000);
2.四川省简阳市人民医院肝胆外科

收稿日期:2022-01-19 修回日期:2023-10-24 出版日期:2023-10-28 发布日期:2024-03-18
通讯作者: 张伟,E-mail:zw68229@sina.com
作者简介:庞武,男,(1982-),硕士,副主任医师,从事肝胆外科的研究。
基金资助:
成都市卫生健康委员会基金(编号:2022631)

The expression of serum miRNA-24 and miRNA-509 in patients with hepatocellular carcinoma and their correlation with prognosis

PANG Wu¹, CHEN Lijiang¹, ZHU Yu¹, WU Yakun¹, ZHANG Wei²

1. Department of hepatobiliary surgery,Suining Central Hospital,Suining 621000,Sichuan province,China;
2. Department of Hepatobiliary Surgery,Jianyang People's Hospital,Sichuan province

Received:2022-01-19 Revised:2023-10-24 Online:2023-10-28 Published:2024-03-18

摘要/Abstract

摘要： 目的探讨肝细胞癌(HCC)患者血清miRNA-24(miR-24)和miRNA-509(miR-509)的表达及临床意义。方法选取2019年1月—2020年10月就诊于四川省遂宁市中心医院的HCC患者94例(HCC组),另选择同期体检中心健康体检者90例(对照组),采用实时定量聚合酶链反应(qRT-PCR)检测人肝癌细胞系及两组入组对象血清中miR-24、miR-509表达水平,探讨miR-24、miR-509水平与HCC临床病理特征及预后的相关性。结果 HCC组患者血清中miR-24表达量明显高于对照组(3.19±0.29vs. 0.66±0.20)(t=-68.601,P＜0.01),miR-509表达量明显低于对照组(0.74±0.27vs. 1.24±0.28)(t=12.331,P＜0.01)。血清中miR-24表达量与甲胎蛋白(AFP)水平、是否转移、TNM分期呈正相关(r=0.821、0.510、0.762,P＜0.01),与分化程度呈负相关(r=-0.771,P＜0.01)。血清中miR-509表达量同AFP水平、是否转移、TNM分期呈负相关(r=-0.820、-0.506、-0.766,P＜0.01),与分化程度呈负相关(r=-0.775,P＜0.01)。结论 HCC患者血清miR-24表达水平上调,而血清miR-509表达下调,同时二者均与HCC转移、恶性程度存在密切关联。临床检测患者血清中miR-24和miR-509水平有助于HCC的诊断及病情评估。

关键词: miR-24, miR-509, 肝细胞癌, 肝癌转移

Abstract: Objective The objective of this study was to investigate the expression and clinical significance of serum miRNA-24 (miR-24) and miRNA-509 (miR-509) in patients with hepatocellular carcinoma (HCC). Methods Ninety-four HCC patients (HCC group) who visited Suining Central Hospital in Sichuan province from January 2019 to October 2020 were selected,and 90 healthy subjects (control group) who underwent the physical examination center at the same time were selected.The expression of miR-24 and miR-509 in human liver cancer cell lines and the serum of participants in the two groups was detected by real-time quantitative polymerase chain reaction (qRT-PCR).The correlation between miR-24 and miR-509 levels and the clinicopathological characteristics and prognosis of HCC was analyzed. Results The expression of miR-24 in the serum of HCC patients was significantly higher than that of the control group (3.19±0.29vs. 0.66 ± 0.20),(t=-68.601,P＜0.01),and the expression of miR-509 was significantly lower than that of the control group(0.74±0.27vs. 1.24 ± 0.28),(t=12.331,P＜0.01).The expression of miR-24 in serum was positively correlated with alpha fetoprotein (AFP) level,metastasis,and TNM stage (r=0.821,0.510,0.762,P＜0.01),and negatively correlated with the degree of differentiation (r=-0.771,P＜0.01).The expression of miR-509 in serum was negatively correlated with AFP level,metastasis and TNM stage (r=-0.820,-0.506,-0.766,P＜0.01),and negatively correlated with the degree of differentiation (r=0.775,P＜0.01). Conclusion The expression of serum mir-24 is up-regulated in HCC patients,while the expression of serum mir-509 is down-regulated.Both of them are closely related to HCC metastasis and malignancy.Clinical testing of serum miR-24 and miR-509 levels in patients can help diagnose and evaluate the condition of HCC.

Key words: miR-24, miR-509, Hepatocellular carcinoma, Liver cancer metastasis

中图分类号:

R735.7

庞武, 陈莉江, 朱宇, 吴涯昆, 张伟. 血清miRNA-24和miRNA-509在肝细胞癌患者血清中的表达及与预后的关系[J]. 实用肿瘤学杂志, 2023, 37(5): 411-415.

PANG Wu, CHEN Lijiang, ZHU Yu, WU Yakun, ZHANG Wei. The expression of serum miRNA-24 and miRNA-509 in patients with hepatocellular carcinoma and their correlation with prognosis[J]. Journal of Practical Oncology, 2023, 37(5): 411-415.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.05.004

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I5/411

参考文献

1 Jiří T,Igor K,Mba.Hepatocellular carcinoma future treatment options[J].Klin Onkol,2020,33(3):26-29.
2 Hartke J,Johnson M,Ghabril M.The diagnosis and treatment of hepatocellular carcinoma[J].Semin Diagn Pathol,2017,34(2):153-159.
3 周俭,彭远飞,王征.余肝不足肝癌手术治疗争议与共识[J].中国实用外科杂志,2018,38(2):126-132.
4 谭妮,郑海平,欧超.肝癌根治术治疗原发性肝癌患者的术后生存率及预后影响因素分析[J].现代肿瘤医学,2019,27(5):826-829.
5 赵鹏伟,黄建钊,柳严,等.原发性肝癌患者术后3年生存率与FHIT基因表达的关系[J].肝脏,2019,24(6):661-664.
6 丁艺洁,盛明薇,张楠,等.原发性肝癌合并肝性脑病患者肝移植术后生存率的回顾性分析[J].实用器官移植电子杂志,2018,6(3):203-208.
7 蔡尚,杨咏强,郭旗,等.胸部肿瘤患者外周血microRNA表达与急性放射性肺炎相关性研究[J].原子能科学技术,2021,55(z2):440-447.
8 刘京豪,韩月婷,陈军.肿瘤细胞外泌体microRNA调控血管生成机制的研究进展[J].癌症,2021,40(5):187-192.
9 Vallianou I,Dafou D,Vassilaki N,et al.Hepatitis C virus suppresses hepatocyte nuclear factor 4 alpha,a key regulator of hepatocellular carcinoma[J].Int J Biochem Cell Biol,2016,78(3):315-326.
10 Yu H,Wei W,Cao W,et al.Regulation of cell proliferation and metastasis by microRNA-593-5p in human gastric cancer[J].Onco Targets Ther,2018,11(2):7429-7440.
11 韩懿存,范修琦,陈玉龙,等.microRNA-34a应用于消化道肿瘤治疗的研究进展[J].郑州大学学报(医学版),2021,56(2):200-204.
12 Oura K,Morishita A,Masaki T.Molecular and functional roles of microRNAs in the progression of hepatocellular carcinoma-a review[J].Int J Mol Sci,2020,7(21):8362.
13 Wu SR,Wu Q,Shi YQ.Recent advances of miRNAs in the development and clinical application of gastric cancer[J].Chin Med J (Engl),2020,133(15):1856-1867.
14 俞忠娜,董燕儿.microRNA抑制卵巢癌细胞VEGF表达及其对肿瘤细胞增殖的影响[J].中华内分泌外科杂志,2019,13(3):233-236.
15 Correia de Sousa M,Gjorgjieva M,Dolicka D,et al.Deciphering miRNAs'action through miRNA editing[J].Int J Mol Sci,2019,20(24):6249.
16 莫辉,徐岷.microRNA-1290在消化系统肿瘤中的研究进展[J].中国医药导报,2020,17(29):48-51.
17 齐媛,郭宝良.microRNA-361-5p在人类恶性肿瘤中的研究进展[J].实用临床医药杂志,2021,25(2):117-121.
18 黄俊辉,钟文良,何兰,等.miRNA在鼻咽癌诊断和治疗中的应用研究进展[J].广西医学,2023,45(12):1472-1478.
19 罗昕,徐铭益.icroRNA-27 a在多种肝脏疾病发生发展中的作用机制[J].临床肝胆病杂志,2020,36(7):1666-1668.
20 王超,梁晓飞,关秀茹.microRNA调控动脉粥样硬化发生发展的研究新进展[J].中华检验医学杂志,2019,42(6):407-413.
21 陈泽山,文彬,丘佩容,等.microRNA-122在肝病发生发展及诊断中的作用[J].临床肝胆病杂志,2021,37(7):1724-1728.
22 杨鹏,滕红丽,罗雪兰,等.miR-24对肝癌MHCC97H细胞增殖、凋亡及迁移能力的影响[J].广西医科大学学报,2019,36(9):1397-1402.
23 朱少美,刘集鸿,周潇.核糖体结合蛋白1干扰慢病毒载体的构建及其对人肝癌细胞的干扰效应[J].国际检验医学杂志,2019,40(5):528-531.
24 何清,李照东,吴小翎.miR-629-5p对胃癌细胞生物学行为的影响及其靶基因MTRF1L的鉴定[J].重庆医科大学学报,2018,43(3):403-409.
25 范维,许芝林,汪大伟,等.微小miRNA-509在肝癌患者血清中的表达及其与预后的关系[J].临床和实验医学杂志,2019,18(3):249-252.

[1]	崔永康, 于承平, 许浩志, 马新宇, 麻勇, 李林强. 营养风险指数在可切除肝细胞癌患者术后并发症及预后预测中的作用[J]. 实用肿瘤学杂志, 2023, 37(3): 243-251.
[2]	殷鼎威, 井杰. 肠道菌群在肝细胞癌中的作用及治疗应用的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 281-286.
[3]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[4]	刘佳, 杨道坤, 王燕平, 陈宝鑫, 王新伟, 申娇. PD-1抑制剂治疗肝细胞癌疗效相关生物标志物的研究现状[J]. 实用肿瘤学杂志, 2022, 36(4): 374-380.
[5]	刘嘉铭, 崔逸峰, 陆朝阳. 槐耳清膏通过线粒体转录因子A调控Akt信号通路进而抑制肝细胞癌的增殖和转移[J]. 实用肿瘤学杂志, 2022, 36(3): 203-207.
[6]	刘雨, 俞星新, 耿志达, 陈政良, 惠鹏, 梁英健. 成纤维细胞在肝癌发生发展中的作用[J]. 实用肿瘤学杂志, 2022, 36(2): 167-172.
[7]	王宗文, 李小东, 朱乾坤, 曾世聪, 翟博. KIF14在肝细胞癌SMCC-7721获得性耐药机制中的研究[J]. 实用肿瘤学杂志, 2022, 36(1): 14-19.
[8]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[9]	纪雷, 纪道林, 鲍冬冬, 谭刚. lncRNA在肝细胞癌索拉非尼耐药中的最新研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 562-567.
[10]	赵浩然, 李满, 张玉宝. 肝细胞癌相关RNA结合蛋白研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 576-579.
[11]	贺玲, 姚克铖. 糖基磷脂酰肌醇转酰胺酶与肝癌[J]. 实用肿瘤学杂志, 2021, 35(5): 458-461.
[12]	曲雁飞, 刘超, 王勃军, 方琳, 张艳桥. CSN6基因在肝细胞癌组织中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(4): 328-333.
[13]	赵凌云, 齐鲁楠, 游雪梅审校. 热休克蛋白70在肝细胞癌中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 528-532.
[14]	赵孟雷. 番茄红素对人肝癌HepG2细胞增殖和凋亡的影响[J]. 实用肿瘤学杂志, 2017, 31(3): 211-216.
[15]	李世杰, 杨奕, 田玉龙, 侯继野, 刘瑞宝. TACE后残余肝癌细胞β-catenin和p28GANK的表达及意义的研究[J]. 实用肿瘤学杂志, 2016, 30(5): 430-435.

血清miRNA-24和miRNA-509在肝细胞癌患者血清中的表达及与预后的关系

The expression of serum miRNA-24 and miRNA-509 in patients with hepatocellular carcinoma and their correlation with prognosis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价